Thrombotic microangiopathy after lung transplantation

Transplantation

Volumn 81, Issue 1, 2006, Pages 57-63

  Hachem, Ramsey R ^a   Yusen, Roger D ^a   Chakinala, Murali M ^a   Aloush, Aviva A ^a   Patterson, G Alexander ^a   Trulock, Elbert P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcineurin inhibitors; Lung transplantation; Thrombotic microangiopathy

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BRONCHIOLITIS OBLITERANS; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PLASMAPHERESIS; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECIPIENT; RISK FACTOR; SURVIVAL TIME; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL RATE; THROMBOSIS;

EID: 31044440553     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000188140.50673.63     Document Type: Article

References (37)

1. Shulman H, Striker G, Deeg HJ, et al. Nephrotoxicity of cyclosporine A after allogeneic marrow transplantation. N Engl J Med 1981; 305: 1393.
2. Atkinson K, Biggs JC, Hayes J, et al. Cyclosporine A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes. Br J Haematol 1983; 54: 59.
3. Powles RL, Clinck HM, Spence D, et al. Cyclosporine to prevent graft-versus-host disease in man after allogeneic bone marrow transplantation. Lancet 1980; 1: 327.
4. Gasser C, Gautier E, Steck A, et al. [Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia]. Schweiz Med Wochenschr 1955; 85: 905.
5. Karmali MA, Steele BT, Petric M, et al. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1983; 1: 619.
6. Amorosi E, Ultmann J. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore) 1966; 45: 139.
7. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589.
8. Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries. Arch Intern Med 1925; 36: 89.
9. Fortin M, Raymond M, Madore F, et al. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am J Transplant 2004; 4: 946.
10. Pham PT, Peng A, Wilkinson AH, et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kid Dis 2000; 36: 844.
11. Trimarchi HM, Truong LD, Brennan S, et al. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. Transplantation 1999; 67: 539.
12. Hachem RR, Chakinala MM, Yusen RD, et al. Thrombotic microangiopathy after lung transplantation [abstract]. J Heart Lung Transplant 2005; 24: A183.
13. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996; 15: 1.
14. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297.
15. Cooper JD, Billingham M, Egan T, et al. A working formulation for the standardization of the nomenclature for clinical staging of chronic allograft dysfunction in lung allografts: International Society for Heart and Lung Transplantation. J Heart Lung Transplant 1993; 12: 713.
16. Seehofer D, Meisel H, Rayes N, et al. Prospective evaluation of the clinical utility of different methods for the detection of human cytomegalovirus disease after liver transplantation. Am J Transplant 2004; 4: 1331.
17. Jeejeebhoy FM, Zaltzman JS. Thrombotic microangiopathy in association with cytomegalovirus infection in a renal transplant patient: a new treatment strategy. Transplantation 1998; 65: 1645.
18. Waiser J, Budde K, Rudolph B, et al. De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection. Am J Kidney Dis 1999; 34: 556.
19. Ramasubbu K, Mullick T, Koo A, et al. Thrombotic microangiopathy and cytomegalovirus in liver transplant recipients: a case-based review. Transplant Infectious Dis 2003; 5: 98.
20. Roberts P, Follette D, Allen R, et al. Cyclosporine A-associated thrombotic thrombocytopenic purpura following lung transplantation. Transplant Proceedings 1998; 30: 1512.
21. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Kidney Int 2001; 60: 831.
22. Langer R, Van Buren C, Katz S, Kahan B. De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination. Transplantation 2002; 73: 756.
23. Paramesh A, Grosskreutz C, Florman S, et al. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation. Transplantation 2004; 77: 129.
24. Randall Y, Fryer J, Thliveris J. Comparison of the effect of rapamycin and FK-506 on release of prostacyclin and endothelin in vitro. Clin Biochem 1993; 26: 409.
25. Babinska, Markell MS, Salifu M, et al. Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dial Transplant 1998; 13: 3153.
26. Saikali J, Truong L, Suki W. Sirolimus may promote thrombotic microangiopathy. Am J Transplant 2003; 3: 229.
27. Robson M, Cote I, Abbs I, et al. Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage. Am J Transplant 2003; 3: 324.
28. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488.
29. Zheng X, Chung C, Takayama TK, et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059.
30. Tsai H, Lian E. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585.
31. Elliott M, Nichols W, Plumhoff E, et al. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. Mayo Clin Proc 2003; 78: 421.
32. Zheng X, Kaufman R, Goodnough L, Sadler J. Effect of plasma exchange on plasma ADAMTS 13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 4043.
33. Arai S, Allan C, Streiff M, et al. Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy. Hematol J 2001; 2: 292.
34. Pham P, Danovitch G, Wilkinson A, et al. Inhibitors of ADAMTS 13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient. Transplantation 2002; 74: 1077.
35. Nakazawa Y, Hashikura Y, Urata K, et al. Von Willebrand factor-cleaving protease activity in thrombotic microangiopathy after living donor liver transplantation: a case report. Liver Transplant 2003; 9: 1328.
36. Maslo C, Peraldi M, Desenclos J, et al. Thrombotic microangiopathy and cytomegalovirus disease in patients infected with human immunodeficiency virus. Clin Infect Dis 1997; 24: 350.
37. Humblot S, Martin T, Pasquali J, Korganow A. Blood coagulation disorders during primary cytomegalovirus infection. Arch Intern Med 2001; 161: 2149.